SCHEMBL721690

SCHEMBL721690

CN(C)c1ccc(-c2ccnc3cc(-c4ccc(-c5cnn(C)c5)cc4)oc23)cn1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AURKB Q96GD4 4/20 0.38
AURKA O14965 2/20 0.38
INCENP Q9NQS7 2/20 0.38
TPX2 Q9ULW0 2/20 0.38
RET P07949 2/20 0.37
CCNC P24863 2/20 0.37
CDK8 P49336 2/20 0.37
APP P05067 2/20 0.36
TTK P33981 1/20 0.36
ALK Q9UM73 1/20 0.36
LRRK2 Q5S007 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
MET P08581 3/20 0.35
MAP4K4 O95819 1/20 0.35
ACVR1 Q04771 1/20 0.35
PIM1 P11309 1/20 0.34
PIM2 Q9P1W9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL723996 0.87 MET (0.40) AURKBCCNCCDK8METMAP4K4
SCHEMBL15209645 0.86 CCNC (0.39) AURKBAURKAINCENPTPX2RET
SCHEMBL723385 0.85 MTOR (0.43) AURKBRETCCNCCDK8ALK
SCHEMBL15209552 0.83 FGFR1 (0.41) RETCCNCCDK8TTKMET
SCHEMBL723758 0.83 DYRK1A (0.47) AURKBAURKAINCENPTPX2CCNC
SCHEMBL722505 0.83 CCNC (0.42) AURKBAURKAINCENPTPX2CCNC
SCHEMBL722999 0.82 CCNC (0.43) RETCCNCCDK8ALKLRRK2
SCHEMBL10268949 0.82 AURKB (0.46) AURKBAURKAINCENPTPX2CCNC
SCHEMBL726778 0.80 AURKB (0.44) AURKBAURKAINCENPTPX2CCNC
SCHEMBL12503590 0.79 MAP3K11 (0.38) AURKBAPPMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB AURKB 1443/4885AURKA 1987/4885INCENP 2945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.